Management Board

President & Chief Executive Officer, “Président du Directoire” (Chairman)


Following the Intercell-Vivalis merger, Thomas Lingelbach was appointed President & CEO of Valneva. He has been with Intercell since 2006, serving as COO until 2011 and since then as CEO. He has held a variety of positions of increasing international responsibility in his more than 25 years in the pharma and vaccine industry. He joined Intercell from Novartis Vaccine & Diagnostics as Managing Director Germany focusing on the integration with Chiron Vaccine where he served as Vice President Global Industrial Operations and Managing Director Chiron-Behring. Thomas Lingelbach holds a Master's degree in Engineering and complemented his education with a Business Administration program.

President & Chief Business Officer,
Directeur Général


Following the Intercell-Vivalis merger, Franck Grimaud was appointed President and Chief Business Officer (CBO) of Valneva. He co-founded Vivalis in 1999 serving as its CEO and “President du Directoire”. He has a long management track record, with more than 20 years of experience in various industries, including 14 years in the biopharmaceutical sector. Before building up Vivalis he was responsible for the creation of the Chinese, Malaysian and Thailand subsidiaries of Groupe Grimaud, a worldwide leader in animal genetic selection and currently Valneva’s largest shareholder. Franck Grimaud holds an MBA from the University of Ottawa (Canada).

Chief Financial Officer,
Directeur Financier


David Lawrence brings over 25 years of experience in the pharmaceutical, biotech and vaccine industries, with a proven international track record in mid-sized to large companies and small biotech start-ups. His tested leadership experience as a CFO in the Lifesciences sector spans across finance and accounting, mergers and acquisitions, fund raising and investor relations. David served as CFO in a dual-listed (LSE and NASDAQ) vaccine biotech company (Acambis plc, acquired by Sanofi in 2008) and was Vice President of Finance & Business Development for Chiron Vaccines, a division of Chiron Corporation which was acquired by Novartis in 2005. Prior to these roles, he held senior finance positions at GlaxoSmithKline including Vice President of Financial Management in Research and Development. In addition, David also brings recent start-up CEO experience and Non-Executive Director/Board experience.

Chief Medical Officer,
Directeur Médical


Dr. Wolfgang Bender, MD, PhD, is a global life sciences leader with over 30 years of extensive experience in scientific-medical affairs, R&D and general management of vaccines and pharmaceuticals. He brings a broad international profile with an exceptional academic background (MD, PhD, MPH, MHA, DTM&P). Wolfgang has special competencies in strategy, operational execution and change management, with a record of success working in leadership roles for leading global life sciences companies. He held a variety of senior and international positions in vaccine development and medical affairs, working for leading companies in the field, including Novartis Vaccines and Takeda Vaccines. Prior positions included country manager, corporate strategy and various clinical research roles at major pharmaceutical companies such as Pfizer and the Hoechst Group.


General Counsel,
Directeur Juridique


Frédéric Jacotot joined Valneva’s Management Board on April 1, 2017. He has been with Valneva since September 2013, in charge of leading the company’s Legal, IP and Compliance functions. Before joining Valneva, he was with Abbott Laboratories as Division Counsel, based in Switzerland. He is a legal expert with experience in international transactions and deep knowledge of the pharmaceutical industry. Frédéric Jacotot holds a Master degree in business law.


photo credits: © CapPhoto

Please update your browser...